In the News
Using mRNA Vaccines to Effectively and Safely Target Infectious Disease and Cancer with Dr. Thomas VanCott and Dr. Romain Micol Combined Therapeutics
News Releases
Combined Therapeutics to Present its Next-Generation mRNA-Based Vaccine Platform at the World Vaccine Congress 2023
BOSTON, March 30, 2023 /PRNewswire/ — Combined Therapeutics Inc. (CTx) today announced its participation in the upcoming World Vaccine Congress 2023, taking place in Washington, D.C., April 4-6, where it will present its cutting-edge mRNA-based vaccine technology MOPCTx in a poster presentation and oral…
Combined Therapeutics Granted Patent for its mRNA Vaccine Platform by USPTO
BOSTON, March 13, 2023 /PRNewswire/ — Combined Therapeutics Inc. (CTx) today announced its intellectual property position reinforcement in mRNA vaccine technology with the issue of U.S. Patent 11,596,685 by the United States Patent and Trademark Office (USPTO) on March 7,…
Combined Therapeutics Expands Board of Directors with Appointments of Biopharma Industry Veterans Paul Wotton, Robert Ruffolo and Kevin F. McLaughlin
BOSTON, March 8, 2023 /PRNewswire/ — Combined Therapeutics Inc. (CTx), a privately held biotechnology company developing the next generation of mRNA therapeutics with a novel modified-mRNA platform to prevent and treat infectious diseases and cancer, today announced the appointment of three highly accomplished biopharma executives to its board of directors: Paul Wotton, Ph.D.;